We’d love to hear your feedback on this activity. It helps us to continually improve our products.
University of Bologna, Bologna, Italy
Prof. Simona Soverini is an associate professor of hematology at the Department of Experimental, Diagnostic and Speciality Medicine of the University of Bologna, and head of the Myeloid Leukemia Research group at the Institute of Hematology “Lorenzo e Ariosto Seragnoli” at the S. Orsola University Hospital in Bologna, Italy. read more
She obtained her MSc in molecular biology and her PhD in clinical and experimental haematology from the University of Bologna. Her research focuses on chronic myeloid leukaemia and systemic mastocytosis. Prof. Soverini is author of over 170 publications in peer-reviewed journals, with a h-index of 50. She is a reviewer for a number of international journals, including Blood, Leukaemia, Haematologica, Clinical Cancer Research and the British Journal of Haematology, and sits in the editorial boards of the Journal of Hematology & Oncology, Frontiers in Oncology and the International Journal of Molecular Sciences. She is a member of the board of directors of the Italian Society of Experimental Hematology (SIES) and a member of the European Hematology Association (EHA), the American Society of Hematology (ASH) and the Society of Hematological Oncology (SOHO). She has served on the scientific program committees for EHA and SOHO congresses.
Prof. Simona Soverini discloses: Advisory board fees from Cepheid and Blueprint Medicines. Consultancy fees from Incyte Biosciences.
University Hospital Brno and Masaryk University, Brno, Czech Republic
Daniela Žáčková, MD, PhD is consultant in haematology and associate professor at the Department of Internal Medicine Hematology and Oncology, University Hospital Brno, and Masaryk University, Brno, Czech Republic. read more
Her scientific interest is mainly focused on the clinical and biological aspects of chronic myeloid leukemia (CML). She acts as a principal investigator of the nationwide, investigator-initiated, TKI-discontinuation, phase II trial HALF; co-investigator and national coordinator of international projects and trials, such as TIGER (CMLV) study, EURO-SKI/AFTER-SKI, PONDEROSA, and Blast Crisis Registry; and expert guarantor and national coordinator of the Czech Registry of CML patients, called INFINITY. She is a member of the European Hematology Association (EHA), European LeukemiaNet (ELN) Working Package 4 (WP4), Czech Leukemia Study Group for Life (CELL). She is on the advisory board of the patient supportive organization ’Diagnóza leukemie’ and an elected chair of the audit committee of the Czech Hematology Association. She is an author or co-author of more than 70 peer-reviewed articles, four scholarly books and eight peer-reviewed textbooks or textbook chapters.
Prof. Daniela Žáčková discloses: Advisory board and speakers bureau fees from Angelini and Novartis. Consultancy fees from Angelini and Novartis. Travel support from Angelini, Bristol Myers Squibb, Novartis and Pfizer.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a
.Explore the latest in medical education and stay current in your field. Create a free account to track your learning.